{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:23:52Z","timestamp":1786994632692,"version":"build-2736575974"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Technological Innovation R&D Program","award":["S2174574"],"award-info":[{"award-number":["S2174574"]}]},{"DOI":"10.13039\/501100003663","name":"Small and Medium Business Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003663","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bio and Medical Technology Development Program","award":["NRF-2014M3A9B5073868"],"award-info":[{"award-number":["NRF-2014M3A9B5073868"]}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"publisher","award":["094152"],"award-info":[{"award-number":["094152"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Faculty of Medicine"},{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.nbd.2018.11.023","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T05:46:14Z","timestamp":1542865574000},"page":"439-453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury"],"prefix":"10.1016","volume":"124","author":[{"given":"Miaad","family":"Bader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Lecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vardit","family":"Rubovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tweedie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Glotfelty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lital","family":"Rachmany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7446-476X","authenticated-orcid":false,"given":"Hee Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Il","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.","family":"Hoffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaim G.","family":"Pick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel H.","family":"Greig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2018.11.023_bb0005","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.neulet.2003.12.005","article-title":"Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze","volume":"361","author":"Alcalay","year":"2004","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nbd.2018.11.023_bb0010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.psyneuen.2015.11.021","article-title":"GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality","volume":"65","author":"Anderberg","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.nbd.2018.11.023_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019562","article-title":"Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial","volume":"8","author":"Antonsen","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.nbd.2018.11.023_bb0020","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.nbd.2018.11.023_bb0025","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.neuropharm.2017.09.023","article-title":"Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease","volume":"136","author":"Athauda","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nbd.2018.11.023_bb0030","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.nbd.2018.11.023_bb0035","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3233\/JPD-181329","article-title":"What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: a Post Hoc Analysis","volume":"8","author":"Athauda","year":"2018","journal-title":"J. Parkinsons. Dis."},{"key":"10.1016\/j.nbd.2018.11.023_bb0040","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson's disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.nbd.2018.11.023_bb0045","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3233\/JPD-140364","article-title":"Motor and Cognitive Advantages Persist 12 months after Exenatide Exposure in Parkinson's","volume":"4","author":"Aviles-Olmos","year":"2014","journal-title":"Disease. J. Parkinsons. Dis."},{"key":"10.1016\/j.nbd.2018.11.023_bb0050","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1089\/neu.2009.0891","article-title":"The Influence of Alcohol on Behavioral Recovery after mTBI in mice","volume":"27","author":"Baratz","year":"2010","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.nbd.2018.11.023_bb0055","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12974-015-0237-4","article-title":"Transiently lowering tumor necrosis factor-\u03b1 synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice","volume":"12","author":"Baratz","year":"2015","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.nbd.2018.11.023_bb0060","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/brain\/awx044","article-title":"Insulin resistance and exendin-4 treatment for multiple system atrophy","volume":"140","author":"Bassil","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2018.11.023_bb0065","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF01108414","article-title":"Cognitive effects of mild head injury in children and adolescents","volume":"3","author":"Beers","year":"1992","journal-title":"Neuropsychol. Rev."},{"key":"10.1016\/j.nbd.2018.11.023_bb0070","first-page":"461","article-title":"The role of microglia and myeloid immune cells in acute cerebral ischemia","volume":"8","author":"Benakis","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.nbd.2018.11.023_bb0075","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jnr.21483","article-title":"Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease","volume":"86","author":"Bertilsson","year":"2008","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.nbd.2018.11.023_bb0080","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.nbd.2018.11.023_bb0085","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.nbd.2018.11.023_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2014.00100","article-title":"A modified controlled cortical impact technique to model mild traumatic brain injury mechanics in mice","volume":"5","author":"Chen","year":"2014","journal-title":"Front. Neurol."},{"issue":"10722","key":"10.1016\/j.nbd.2018.11.023_bb0095","article-title":"Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease","volume":"8","author":"Chen","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nbd.2018.11.023_bb0100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4093\/dmj.2016.40.2.99","article-title":"An Update on the effect of Incretin-based Therapies on \u03b2-Cell Function and Mass","volume":"40","author":"Chon","year":"2016","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.nbd.2018.11.023_bb0105","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bandc.2004.08.002","article-title":"The long-term effects of mild head injury on short-term memory for visual form, spatial location, and their conjunction in well-functioning university students","volume":"56","author":"Chuah","year":"2004","journal-title":"Brain Cogn."},{"key":"10.1016\/j.nbd.2018.11.023_bb0110","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jneumeth.2016.02.002","article-title":"Novel pharmaceutical treatments for minimal traumatic brain injury and evaluation of animal models and methodologies supporting their development","volume":"272","author":"Deselms","year":"2016","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.nbd.2018.11.023_bb0115","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1089\/dia.2011.0050","article-title":"Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes","volume":"13","author":"Deyoung","year":"2011","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.nbd.2018.11.023_bb0120","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0166-4328(98)00079-5","article-title":"Extending the spontaneous preference test of recognition: evidence of object-location and object-context recognition","volume":"99","author":"Dix","year":"1999","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.nbd.2018.11.023_bb0125","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.nbd.2018.11.023_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082016","article-title":"Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats","volume":"8","author":"Eakin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2018.11.023_bb0135","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00213-010-2098-y","article-title":"The intriguing effects of ecstasy (MDMA) on cognitive function in mice subjected to a minimal traumatic brain injury (mTBI)","volume":"214","author":"Edut","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nbd.2018.11.023_bb0140","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S2215-0366(18)30065-8","article-title":"Long-term risk of dementia among people with traumatic brain injury in Denmark: a population-based observational cohort study","volume":"5","author":"Fann","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.nbd.2018.11.023_bb0145","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbi.2006.03.005","article-title":"Microglia serve as a neuroimmune substrate for stress-induced potentiation of CNS pro-inflammatory cytokine responses","volume":"21","author":"Frank","year":"2007","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.nbd.2018.11.023_bb0150","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2174\/187152711794653751","article-title":"Targeting TNF-\u03b1 to elucidate and ameliorate neuroinflammation in neurodegenerative diseases","volume":"10","author":"Frankola","year":"2011","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.nbd.2018.11.023_bb0155","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s12020-014-0223-0","article-title":"Extra-pancreatic effects of incretin-based therapies","volume":"47","author":"Gallwitz","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.nbd.2018.11.023_bb0160","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.mcn.2015.03.001","article-title":"Epidemiology of mild traumatic brain injury and neurodegenerative disease","volume":"66","author":"Gardner","year":"2015","journal-title":"Mol. Cell. Neurosci."},{"issue":"108","key":"10.1016\/j.nbd.2018.11.023_bb0165","article-title":"Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.nbd.2018.11.023_bb0170","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/laban1005-39","article-title":"A rapid, simple, and humane method for submandibular bleeding of mice using a lancet","volume":"34","author":"Golde","year":"2005","journal-title":"Lab Anim. (NY)."},{"key":"10.1016\/j.nbd.2018.11.023_bb0175","first-page":"134ra60","article-title":"Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model","volume":"4","author":"Goldstein","year":"2012","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.nbd.2018.11.023_bb0180","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1167\/iovs.15-19006","article-title":"Protective effect of a GLP-1 analog on ischemia-reperfusion induced blood-retinal barrier breakdown and inflammation","volume":"57","author":"Gon\u00e7alves","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.nbd.2018.11.023_bb0185","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jalz.2013.12.011","article-title":"Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury","volume":"10","author":"Greig","year":"2014","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nbd.2018.11.023_bb0190","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.clinthera.2013.12.002","article-title":"Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study","volume":"36","author":"Gu","year":"2014","journal-title":"Clin. Ther."},{"issue":"500","key":"10.1016\/j.nbd.2018.11.023_bb0195","article-title":"Plant polyphenols and exendin-4 prevent hyperactivity and TNF-\u03b1 release in LPS-treated in vitro neuron\/astrocyte\/microglial networks","volume":"11","author":"Gullo","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.nbd.2018.11.023_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120074","article-title":"Preservation of the blood brain barrier and cortical neuronal tissue by liraglutide, a long acting glucagon-like-1 analogue, after experimental traumatic brain injury","volume":"10","author":"Hakon","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2018.11.023_bb0205","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/WNR.0b013e32832fbf14","article-title":"Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system","volume":"20","author":"Hamilton","year":"2009","journal-title":"Neuroreport"},{"key":"10.1016\/j.nbd.2018.11.023_bb0210","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1476-5381.2009.00486.x","article-title":"Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection","volume":"159","author":"Harkavyi","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nbd.2018.11.023_bb0215","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1210\/en.2014-1675","article-title":"Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain","volume":"156","author":"Heppner","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.nbd.2018.11.023_bb0220","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1523\/JNEUROSCI.4526-04.2005","article-title":"Isotropic fractionator: a simple, rapid method for the quantification of total cell and neuron numbers in the brain","volume":"25","author":"Herculano-Houzel","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2018.11.023_bb0225","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.neuropharm.2018.01.040","article-title":"Novel dual GLP-1\/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models","volume":"136","author":"H\u00f6lscher","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nbd.2018.11.023_bb0230","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3233\/NRE-2007-22502","article-title":"The impact of traumatic brain injuries: a global perspective","volume":"22","author":"Hyder","year":"2007","journal-title":"NeuroRehabilitation"},{"key":"10.1016\/j.nbd.2018.11.023_bb0235","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ejphar.2010.10.008","article-title":"The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test","volume":"650","author":"Isacson","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.nbd.2018.11.023_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-328X(98)00040-0","article-title":"Microglia-specific localisation of a novel calcium binding protein, Iba1","volume":"57","author":"Ito","year":"1998","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.nbd.2018.11.023_bb0245","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.neures.2006.04.008","article-title":"Glucagon-like peptide-1 inhibits LPS-induced IL-1\u03b2 production in cultured rat astrocytes","volume":"55","author":"Iwai","year":"2006","journal-title":"Neurosci. Res."},{"issue":"766","key":"10.1016\/j.nbd.2018.11.023_bb0250","article-title":"GLP-1 secretion by microglial cells and decreased CNS expression in obesity","volume":"9","author":"Kappe","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.nbd.2018.11.023_bb0255","doi-asserted-by":"crossref","DOI":"10.1089\/neu.2018.5898","article-title":"Neuronal enriched eExtracellular vesicle proteins as biomarkers for traumatic brain injury","author":"Karnati","year":"2018","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.nbd.2018.11.023_bb0260","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.ijo.0802206","article-title":"Entry of exendin-4 into brain is rapid but may be limited at high doses","volume":"27","author":"Kastin","year":"2003","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.nbd.2018.11.023_bb0265","doi-asserted-by":"crossref","first-page":"07","DOI":"10.1385\/JMN:18:1-2:07","article-title":"Interactions of Glucagon-like Peptide-1 (GLP-1) with the Blood-Brain Barrier","volume":"18","author":"Kastin","year":"2002","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.nbd.2018.11.023_bb0270","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1677\/JOE-09-0132","article-title":"Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease","volume":"202","author":"Kim","year":"2009","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.nbd.2018.11.023_bb0275","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1177\/0963689717721234","article-title":"A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: the Glucagon-like Peptide-1 Receptor Pathway","volume":"26","author":"Kim","year":"2017","journal-title":"Cell Transplant."},{"key":"10.1016\/j.nbd.2018.11.023_bb0280","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.2337\/db14-0883","article-title":"Glucagon-like Peptide-1 Receptor Agonists increase Pancreatic Mass by Induction of Protein Synthesis","volume":"64","author":"Koehler","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.nbd.2018.11.023_bb0285","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1017\/S0033291710001728","article-title":"Long-term cognitive and emotional consequences of mild traumatic brain injury","volume":"41","author":"Konrad","year":"2011","journal-title":"Psychol. Med."},{"key":"10.1016\/j.nbd.2018.11.023_bb0290","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.brainresrev.2004.12.009","article-title":"Microglial cell population dynamics in the injured adult central nervous system","volume":"48","author":"Ladeby","year":"2005","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.nbd.2018.11.023_bb0295","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00001199-200609000-00001","article-title":"The Epidemiology and Impact of Traumatic Brain Injury: A Brief Overview","volume":"21","author":"Langlois","year":"2006","journal-title":"J. Head Trauma Rehabil."},{"key":"10.1016\/j.nbd.2018.11.023_bb0300","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1007\/s12035-017-0550-2","article-title":"Activation of Glucagon-like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by reducing Neuroinflammatory responses","volume":"55","author":"Lee","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.nbd.2018.11.023_bb0305","author":"Lewis"},{"key":"10.1016\/j.nbd.2018.11.023_bb0310","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0806720106","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","volume":"106","author":"Li","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2018.11.023_bb0315","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3233\/JAD-2010-1314","article-title":"GLP-1 Receptor Stimulation Reduces Amyloid-\u03b2 Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease","volume":"19","author":"Li","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.nbd.2018.11.023_bb0320","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/j.1471-4159.2010.06731.x","article-title":"Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells","volume":"113","author":"Li","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2018.11.023_bb0325","article-title":"Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2018.11.023_bb0330","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/jnc.13169","article-title":"Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice","volume":"135","author":"Li","year":"2015","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2018.11.023_bb0335","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1515\/revneuro-2016-0018","article-title":"Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases","volume":"27","author":"Li","year":"2016","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.nbd.2018.11.023_bb0340","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0006-8993(95)00490-H","article-title":"Eicosanoids are produced by microglia, not by astrocytes, in rat glial cell cultures","volume":"685","author":"Matsuo","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2018.11.023_bb0345","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/neu.2005.22.1003","article-title":"Mild Traumatic Brain Injury Induces Persistent Cognitive Deficits and Behavioral Disturbances in mice","volume":"22","author":"Milman","year":"2005","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.nbd.2018.11.023_bb0350","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/17425255.2018.1420160","article-title":"Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes","volume":"14","author":"Molina Vega","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.nbd.2018.11.023_bb0355","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/bja\/aem128","article-title":"Traumatic brain injury: assessment, resuscitation and early management","volume":"99","author":"Moppett","year":"2007","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.nbd.2018.11.023_bb0360","doi-asserted-by":"crossref","first-page":"H1022","DOI":"10.1152\/ajpheart.2000.279.3.H1022","article-title":"Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique","volume":"279","author":"Murakami","year":"2000","journal-title":"Am. J. Physiol. Circ. Physiol."},{"issue":"278","key":"10.1016\/j.nbd.2018.11.023_bb0365","article-title":"Plasma extracellular vesicles enriched for neuronal origin: a potential window into brain pathologic processes","volume":"11","author":"Mustapic","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.nbd.2018.11.023_bb0370","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.12591","article-title":"Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"18","author":"Nauck","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.nbd.2018.11.023_bb0375","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00221-002-1355-7","article-title":"Increased hippocampal uptake of tumor necrosis factor alpha and behavioral changes in mice","volume":"149","author":"Pan","year":"2003","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.nbd.2018.11.023_bb0380","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1124\/jpet.102.037481","article-title":"Protection and Reversal of Excitotoxic Neuronal damage by Glucagon-like Peptide-1 and Exendin-4","volume":"302","author":"Perry","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.nbd.2018.11.023_bb0385","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1124\/jpet.300.3.958","article-title":"A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells","volume":"300","author":"Perry","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.nbd.2018.11.023_bb0390","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.expneurol.2006.09.028","article-title":"Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy","volume":"203","author":"Perry","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2018.11.023_bb0395","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijdevneu.2011.05.009","article-title":"Repeat traumatic brain injury in the developing brain","volume":"30","author":"Prins","year":"2012","journal-title":"Int. J. Dev. Neurosci."},{"key":"10.1016\/j.nbd.2018.11.023_bb0400","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s11357-012-9464-0","article-title":"Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice","volume":"35","author":"Rachmany","year":"2013","journal-title":"Age (Omaha)."},{"issue":"3735","key":"10.1016\/j.nbd.2018.11.023_bb0405","article-title":"Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degeneration","volume":"7","author":"Rachmany","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nbd.2018.11.023_bb0410","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2011-000312","article-title":"A case-control study examining whether neurological deficits and PTSD in combat veterans are related to episodes of mild TBI","volume":"2","author":"Ruff","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.nbd.2018.11.023_bb0415","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11096-012-9729-9","article-title":"Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction","volume":"35","author":"Russell","year":"2013","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.nbd.2018.11.023_bb0420","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1476-5381.2012.01971.x","article-title":"Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders","volume":"166","author":"Salcedo","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nbd.2018.11.023_bb0425","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.brainres.2016.03.053","article-title":"Development and application of novel histochemical tracers for localizing brain connectivity and pathology","volume":"1645","author":"Schmued","year":"2016","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2018.11.023_bb0430","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3171\/2013.1.JNS121130","article-title":"In-hospital mortality after traumatic brain injury surgery: a nationwide population-based comparison of mortality predictors used in artificial neural network and logistic regression models","volume":"118","author":"Shi","year":"2013","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.nbd.2018.11.023_bb0435","first-page":"157","article-title":"Humans with Traumatic Brain Injuries Show Place-Learning Deficits in Computer-Generated Virtual Space","volume":"22","author":"Skelton","year":"2000","journal-title":"Neuropsychology, Dev. Cogn. Sect. A"},{"key":"10.1016\/j.nbd.2018.11.023_bb0440","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0301-0082(98)00069-0","article-title":"Reactive microgliosis","volume":"57","author":"Streit","year":"1999","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.nbd.2018.11.023_bb0445","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1159\/000490017","article-title":"Exendin-4 Plays a protective Role in a Rat Model of Spinal Cord Injury through SERCA2","volume":"47","author":"Sun","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.nbd.2018.11.023_bb0450","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00701-005-0651-y","article-title":"A systematic review of brain injury epidemiology in Europe","volume":"148","author":"Tagliaferri","year":"2006","journal-title":"Acta Neurochir."},{"key":"10.1016\/j.nbd.2018.11.023_bb0455","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.expneurol.2016.11.005","article-title":"Novel GLP-1R\/GIPR co-agonist \u201ctwincretin\u201d is neuroprotective in cell and rodent models of mild traumatic brain injury","volume":"288","author":"Tamargo","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2018.11.023_bb0460","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/jcbfm.2011.51","article-title":"Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia","volume":"31","author":"Teramoto","year":"2011","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.nbd.2018.11.023_bb0465","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1113\/jphysiol.2008.164012","article-title":"Nutritional regulation of glucagon-like peptide-1 secretion","volume":"587","author":"Tolhurst","year":"2009","journal-title":"J. Physiol."},{"key":"10.1016\/j.nbd.2018.11.023_bb0470","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/jnr.21160","article-title":"Apoptotic and behavioral sequelae of mild brain trauma in mice","volume":"85","author":"Tweedie","year":"2007","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.nbd.2018.11.023_bb0475","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.expneurol.2012.10.001","article-title":"Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice","volume":"239","author":"Tweedie","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2018.11.023_bb0480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156493","article-title":"Cognitive Impairments Induced by Concussive Mild Traumatic Brain Injury in Mouse are Ameliorated by Treatment with Phenserine via Multiple Non-Cholinergic and Cholinergic Mechanisms","volume":"11","author":"Tweedie","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2018.11.023_bb0485","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jalz.2015.07.489","article-title":"Blast traumatic brain injury-induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4","volume":"12","author":"Tweedie","year":"2016","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nbd.2018.11.023_bb0490","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/14728222.2018.1487952","article-title":"Targeting glucose-dependent insulinotropic polypeptide receptor for neurodegenerative disorders","volume":"22","author":"Verma","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.nbd.2018.11.023_bb0495","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1089\/neu.2012.2456","article-title":"The effect of injury severity on behavior: a phenotypic study of cognitive and emotional deficits after mild, moderate, and severe controlled cortical impact injury in mice","volume":"29","author":"Washington","year":"2012","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.nbd.2018.11.023_bb0500","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jneuroim.2017.12.005","article-title":"Both classic Gs-cAMP\/PKA\/CREB and alternative Gs-cAMP\/PKA\/p38\u03b2\/CREB signal pathways mediate exenatide-stimulated expression of M2 microglial markers","volume":"316","author":"Wu","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.nbd.2018.11.023_bb0505","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.neuropharm.2017.09.040","article-title":"Exendin-4 attenuates neuronal death via GLP-1R\/PI3K\/Akt pathway in early brain injury after subarachnoid hemorrhage in rats","volume":"128","author":"Xie","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nbd.2018.11.023_bb0510","article-title":"Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease","volume":"1","author":"Yun","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2018.11.023_bb0515","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0306-4522(03)00048-4","article-title":"Closed-head minimal traumatic brain injury produces long-term cognitive deficits in mice","volume":"118","author":"Zohar","year":"2003","journal-title":"Neuroscience"}],"updated-by":[{"DOI":"10.1016\/j.nbd.2024.106563","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000}}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996118306697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996118306697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T13:24:09Z","timestamp":1720790649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996118306697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":103,"alternative-id":["S0969996118306697"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2018.11.023","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2018.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}